GlobalData: Upcoming Novartis chronic heart failure drug expected to dominate market by 2022


By Mia Burns

Research and consulting firm has released a new report, PharmaPoint: Chronic Heart Failure – Global Drug Forecast and Market Analysis to 2022 and forecasts global sales of ’ combination LCZ-696 to reach a massive $ 1.86 billion by .  GlobalData estimates that 15 to 20 percent of all patients across the United States and Europe treated with the drug by the end of the forecast period. LCZ-696 is to enter the U.S. and EU markets in 2015 and 2016, and according to GlobalData, the drug will rapidly the global chronic heart failure therapeutics sector and mark a drug development paradigm shift.

“The CHF is primarily dominated by cheaply priced generics,” says Claire Herman, director of CVMD and Infectious Diseases, GlobalData. “Novartis’ novel combination drug LCZ-696 in 2015 will mark the first entrance of a novel branded CHF drug in the past five years, boosting the overall size considerably during the forecast period, 2012-2022. The ACE inhibitor class of drugs is one of the main standards of care in a vast majority of CHF patients.  LCZ-696 is currently in a head-to -head, Phase III trial with an ACE inhibitor, enalapril. Interviewed key opinion leaders in the field of CHF suggest that if LCZ-696 is proven to be significantly superior to enalapril then it could potentially replace ACE inhibitors, ARBs and other key drugs in the CHF treatment paradigm.”

LCZ-696 is being evaluated in a trial for patients with heart failure with reduced ejection fraction, Herman told Med Ad News, but if clinical trial data continue to demonstrate the drug’s efficacy in patients with heart failure with preserved…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS